IMPORTANCE OF CLASSIFICATION AND REASSESSMENT IN PATIENTS WITH PAH-CHD: THE NORPAP DATABASE

被引：0
|
作者：
Bingham, R. [1 ]
Abraham, D. [1 ,2 ]
Baral, R. [1 ]
Edge, H. [1 ]
Head, C. [2 ]
Lewis, C. [3 ]
Freeman, L. J. [1 ,2 ,3 ]
机构：
[1] Univ East Anglia, Norwich, Norfolk, England
[2] Norfolk & Norwich Univ NHS Fdn Trust, Norwich, Norfolk, England
[3] Papworth Hosp NHS Fdn Trust, Papworth Everard, England
来源：
HEART | 2018年 / 104卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1
引用
收藏
页码：A1 / A1
页数：1
相关论文
共 50 条
  • [1] IMPORTANCE OF CLASSIFICATION AND REASSESSMENT IN PATIENTS WITH PAH-CHD: THE NORPAP DATABASE
    Abraham, Dilip
    Bingham, Ruth
    Ranu, Ranu
    Head, Catherine
    Lewis, Clive
    Freeman, Leisa J.
    HEART, 2017, 103 : A54 - A55
  • [2] GENOMICS IN ADULT PATIENTS WITH CONGENITAL HEART DISEASE (CHD): THE NORPAP DATABASE
    Rafiq, Isma
    Freeman, Leisa
    Lewis, Clive
    HEART, 2015, 101 : A81 - A82
  • [3] A multi-biomarker model identifies patients with PAH-CHD at highest risk for mortality
    Van Dissel, A. C.
    Blok, I. M.
    Zwinderman, A. H.
    Van Dijk, A. P. J.
    Duijnhouwer, A. L.
    Mulder, B. J. M.
    Bouma, B. J.
    EUROPEAN HEART JOURNAL, 2017, 38 : 430 - 430
  • [4] Differences in right ventricular function and response to targeted therapy between patients with IPAH and PAH-CHD
    Zhu, Tengteng
    Wu, Panyun
    Tan, Zhen
    Jin, Quan
    Chen, Yusi
    Li, Lian
    Chen, Zewei
    Tang, Yirui
    Li, Jiang
    Fang, Zhenfei
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [5] Right ventricular filling properties improve with Endothelin Receptor Antagonists in PAH-CHD
    De-Bon, H. A. C. M. Bruin
    Blok, I. M.
    Van Dissel, A. C.
    Van Dijk, A. P. J.
    Duijnhouwer, A. L.
    Van den Brink, R. B. A.
    Mulder, B. J. M.
    Bouma, B. J.
    EUROPEAN HEART JOURNAL, 2017, 38 : 952 - 952
  • [6] Mortality rates according to deterioration of various follow-up parameters in PAH-CHD
    Schuijt, M. T. U.
    Blok, I. M.
    Van Riel, A. C. M. J.
    Zwinderman, A. H.
    Van Dijk, A. P. J.
    Mulder, B. J. M.
    Bouma, B. J.
    EUROPEAN HEART JOURNAL, 2016, 37 : 26 - 27
  • [7] Insight into Pulmonary Arterial Hypertension Associated with Congenital Heart Disease (PAH-CHD): Classification and Pharmacological Management from a Pediatric Cardiological Point of View
    Chen, I-Chen
    Dai, Zen-Kong
    ACTA CARDIOLOGICA SINICA, 2015, 31 (06) : 507 - 515
  • [8] Evaluating the role of serum uric acid in the risk stratification and therapeutic response of patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD)
    Luo, Jun
    Li, Yuanchang
    Chen, Jingyuan
    Qiu, Haihua
    Chen, Wenjie
    Luo, Xiaoqin
    Chen, Yusi
    Tan, Yingjie
    Li, Jiang
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [9] High-risk pregnancy in a patient with pulmonary arterial hypertension due to congenital heart disease (PAH-CHD) with temporary shunt inversion and deoxygenation
    Hohmann, Christopher
    Dumitrescu, Daniel
    Gerhardt, Felix
    Kramer, Tilmann
    Rosenkranz, Stephan
    Huntgeburth, Michael
    PULMONARY CIRCULATION, 2019, 9 (02)
  • [10] Selexipag for pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) after defect correction: insights from the randomized controlled GRIPHON study
    Beghetti, M.
    Channick, R.
    Chin, K.
    Di Scala, L.
    Gaine, S.
    Ghofrani, H. A.
    Hoeper, M.
    Lang, I.
    McLaughlin, V.
    Preiss, R.
    Rubin, L.
    Simonneau, G.
    Sitbon, O.
    Tapson, V.
    Galie, N.
    EUROPEAN HEART JOURNAL, 2016, 37 : 1243 - 1243
12345